Company Overview and News

1
IDRA / Idera Pharmaceuticals, Inc. / Baker Brothers Advisors LP - SC 13D/A (Activist Investment)

2018-09-20 sec.gov
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 IDRA

6
IDRA / Idera Pharmaceuticals, Inc. / Baker Brothers Advisors LP - SC 13D/A (Activist Investment)

2018-09-20 sec.gov - 5
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 IDRA

3
11
Idera Pharmaceuticals Announces Appointment of Howard Pien to its Board of Directors

2018-09-18 globenewswire
EXTON, Pa., Sept. 18, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a pharmaceutical company focused on the development and commercialization of its proprietary immune modulator, tilsotolimod, for the treatment of cancer, today announced that Howard Pien joined its Board of Directors, effective September 18, 2018.
ABT SAGE INVVY IDRAW JUNO IDRA VNDA IZQVF ABT

3
IDRA / Idera Pharmaceuticals, Inc. 8-K (Current Report)

2018-09-13 sec.gov - 2
UNITED STATES<
IDRA

1
Idera Pharmaceuticals Announces Corporate Organizational Changes

2018-09-11 globenewswire
- Bryant D. Lim appointed as General Counsel and Secretary of the Board of Directors -
IDRAW IDRA INCY

2
IDRA / Idera Pharmaceuticals, Inc. / Castellina Ventures Ltd. - SC 13G (Passive Investment)

2018-09-04 sec.gov - 1
SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
IDRA

1
IDRA / Idera Pharmaceuticals, Inc. / Castellina Ventures Ltd. - SC 13G (Passive Investment)

2018-09-04 sec.gov
SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
IDRA

1
IDRA / Idera Pharmaceuticals, Inc. null

2018-09-04 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C0R(# @;V)J#3P\+TQI;F5A;\! @P M (H'[ T*96YD
IDRA

1
Idera Pharmaceuticals to Present at the H.C. Wainwright 20th Annual Global Investment Conference

2018-08-30 globenewswire
EXTON, Pa., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a pharmaceutical company focused on the development and commercialization of its proprietary immune modulator, tilsotolimod, for the treatment of cancer, today announced that the company will participate in the H.C. Wainwright 20th Annual Global Investment Conference on Wednesday, September 5, 2018 at 2:10 p.m.
IDRAW IDRA

1
BioCryst Reports Second Quarter 2018 Financial Results

2018-08-07 globenewswire
RESEARCH TRIANGLE PARK, N.C., Aug. 07, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today financial results for the second quarter ended June 30, 2018.
IDRAW IDRA BCRX

1
Idera Pharmaceuticals (IDRA) Reports Q2 Loss, Lags Revenue Estimates

2018-08-02 zacks
Idera Pharmaceuticals (IDRA - Free Report) just came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.80. This compares to loss of $1.12 per share a year ago. These figures are adjusted for non-recurring items.
SHAK IDRAW IDRA

1
Idera Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update

2018-08-02 globenewswire
Abstract accepted for 2018 European Society of Medical Oncology Annual Meeting Cash runway into first quarter of 2020
IDRAW IDRA BCRX

1
IDRA / Idera Pharmaceuticals, Inc. 10-Q (Quarterly Report)

2018-08-02 sec.gov
IDRA_Current_Folio_10Q2 Table of Contents
IDRA

1
ECA2018-125 - Reverse Split and CUSIP Number Change for Idera Pharmaceuticals, Inc. (IDRA)

2018-07-27 nasdaqtrader
Idera Pharmaceuticals, Inc. (IDRA) will effect a one-for-eight (1-8) reverse split of its common stock. The reverse stock split will become effective on Monday, July 30, 2018. In conjunction with the reverse split, the CUSIP number will change to 45168K405.
IDRAW IDRA

IDRA : Idera Pharmaceuticals Stock Analysis and Research Report

2017-10-23 - Asif

Idera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel oligonucleotide therapeutics for oncology and rare diseases. Idera Pharmaceuticals use two distinct proprietary drug discovery technology platforms to design and develop drug candidates: its Toll-like receptor, or TLR, targeting technology and its third-generation antisense, or 3GA, technology. Idera Pharmaceuticals developed these platforms based on its scientific expertise and pioneering work with synthetic oligonucleotides as therapeutic agents. Using its TLR targeting technology, Idera Pharmaceuticals design synthetic oligonucleotide-based drug candidates to modulate the activity of specific TLRs. In addition, using its 3GA technology, Idera Pharmaceuticals is developing drug candidates to turn off the messenger RNA, or mRNA, associated with disease causing genes. Idera Pharmaceuticals believe its 3GA technology may potentially reduce the immunoto...

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to IDRA / Idera Pharmaceuticals, Inc. on message board site Silicon Investor.

IDRA Baker Bros on board u0026 Vincent Millano IDRA Baker Bros on board u0026 Vincent Millano IDRA Baker Bros on board u0026 Vincent Millano IDRA IDRA IDRA
CUSIP: 45168K306